The EPI-PEP-VAC consortium will use cutting-edge research and the most advanced technologies to elucidate the structural, biochemical and cellular basis of the immune response to exogenously delivered peptide epitopes, with the central objective of defining basic rules for the selection and optimisation of peptide vaccine candidates. The research will be focused on a pathogen of major health and socio-economical importance in the EU, namely human cytomegalovirus (HCMV). Novel strategies, technologies and read-out assays will be developed for peptide definition, modelling and screening to achieve optimal peptide performance. Animal models and ex-vivo models for follow-up will be developed and used for establishment of diagnostic tools and to optimise delivery system and immunization route of peptide vaccines.
Funding SchemeCSC - Cost-sharing contracts
79108 Freiburg (In Breisgau)